News & Updates

Latest findings from the ongoing phase III NATALEE trial have shown that 3-year treatment with adjuvant ribociclib, in combination with a nonsteroidal aromatase inhibitor (NSAI), remained well tolerated in patients with HR+/HER2- early-stage breast cancer (EBC).

New research has shown that a low-fat vegan diet rich in vegetables, fruits, whole grains, and legumes can improve insulin sensitivity in adult patients with type 1 diabetes (T1D), thus reducing their daily insulin requirements. The finding may fuel the momentum for dietary shifts in this population.

Poor glycaemic control appears to contribute to coronary stent failure driven by in-stent restenosis in patients with type 2 diabetes (T2D), suggests a study.

The direct oral anticoagulants (DOACs) apixaban and rivaroxaban trump warfarin for the treatment of venous thromboembolism (VTE) in a retrospective observational analysis comprising real-world VTE patients from Finland, Norway, and Sweden.

Long-term follow-up of the DESTINY-Breast03 trial has reported a median overall survival (OS) of 52.6 months with trastuzumab deruxtecan (T-DXd), representing the longest reported OS in previously treated HER2-positive metastatic breast cancer (mBC) to date.